Apeiron Therapeutics
PrivateLast Round
Series A
Mar 29, 2022
Total Funding Raised
$44.5M
Company Overview
Apeiron Therapeutics operates in Healthcare & Life Sciences and is based in Burlingame, California. Its latest recorded funding round was a Series A round in March 2022.
Apeiron Therapeutics is a biotechnology company that develops biomarker-driven cancer therapeutics using a structure-based, AI-driven drug design platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apeiron Therapeutics Comparables
Compare Apeiron Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Recursion Pharmaceuticals | 81% | |
| Tango Therapeutics | 80% | |
| Bristol Myers Squibb | 78% |
For institutional investors. Book with your work email.
Apeiron Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 29, 2022 | ||||
| Seed | Jun 11, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Apeiron Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Viva BioInnovator | Series A |
| GT Healthcare Capital Partners | Seed |
| Panacea Venture Healthcare | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Monthly visitors grew 80% MoM, reaching 1.2K.
- May 1, 2025
Monthly visitors grew 298% MoM, from 377 to 1.5K.
For institutional investors. Book with your work email.
Apeiron Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Apeiron Therapeutics's valuation, stock price, and market status.
Is Apeiron Therapeutics a public or private company?
Apeiron Therapeutics is a private company.
What is the current stock price of Apeiron Therapeutics?
Apeiron Therapeutics is a private company, so its shares have no public market price. Caplight tracks Apeiron Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Apeiron Therapeutics worth (valuation)?
Valuation information for Apeiron Therapeutics is not publicly available.
Can I buy Apeiron Therapeutics stock?
Apeiron Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Apeiron Therapeutics's last funding round?
Apeiron Therapeutics's most recent funding round was Series A on March 29, 2022.
Who are the main investors in Apeiron Therapeutics?
Key investors in Apeiron Therapeutics include GT Healthcare Capital Partners, Panacea Venture Healthcare.
Will Apeiron Therapeutics IPO soon?
No public IPO plans have been announced for Apeiron Therapeutics.
How can I track Apeiron Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Apeiron Therapeutics's shares on secondary markets.